Further, selective clearing of p16‐expressing cells with a genetic approach or removing senescent cells with senolytic compounds in AD mouse models have been shown to ameliorates various aspects of AD pathologies including tau phosphorylation, NFTs formation, Aβ load, and cognitive decline (Bussian et al. 2018; Hu et al. 2021; Musi et al. 2018; Zhang et al. 2019). The gene discussed is MAPT; the disease is Alzheimer disease.